Understanding the PRoFESS study for secondary stroke prevention

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 3, 2009, Pages 221-231

  Schneck, Michael J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EPROSARTAN; INDAPAMIDE; LOSARTAN; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TICLOPIDINE; VALSARTAN; WARFARIN;

ANGIONEUROTIC EDEMA; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PRURITUS; PURPURA; RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 65549085735     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0023-7     Document Type: Review

References (48)

1. Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart disease and stroke statistics - 2009 update. Circulation 2008, 108:e1-e162.
2. Schneck MJ: Antiplatelet therapy. In Transient Ischemic Attacks. Edited by Chaturvedi S, Levine SR. Armonk, NY: Futura; 2004:233-252.
3. Gebel JM Jr: Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient. J Am Coll Cardiol 2005, 46:752-805.
4. Albers GW: Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients? Neurology 2000, 54:1022-1028.
5. Vickrey BG, Rector TS, Wickstrom SL, et al.: Occurrence of secondary ischemic events among patients with atherosclerotic vascular disease. Stroke 2002, 33:901-906.
6. Fletcher GF, Bufalino V, Costa F, et al.: Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol 2007, 99:e1-e35.
7. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348:1329-1339.
8. Ringleb PA, Bhatt DL, Hirsch AT, et al.; for the CAPRIE Investigators: Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004, 35:528-532.
9. European Stroke Prevention Study Group: European Stroke Prevention Study principal end-points. Lancet 1987, 2:1351-1354.
10. Diener HC, Cunhla L, Fobers C, et al.: European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
11. Halkes PH, van Gijn J, Kappellle LJ, et al.: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT). Lancet 2006, 367:1665-1673.
12. Yusuf S, Shao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 2001, 345:494-502.
13. Diener H-C, Bogousslavsky J, Brass LM, et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomized double blind placebo-controlled trial. Lancet 2004, 364:331-337.
14. Bhatt DL, Fox KA, Hacke W, et al.; for the CHARISMA Investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
15. Wilterdink JL, Easton JD: Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999, 56:1087-1092.
16. Moussouttas M: Emerging therapies: Esprit [letter to the editor]. Stroke 2006, 38: 1142.
17. Ariesen M-J, Algra A, Kappelle LJ: Antiplatelet drugs in the secondary prevention after stroke: Differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006, 37:134-138.
18. Liao JK: Secondary prevention of stroke and transient ischemic attack. Is more platelet inhibition the answer? Circulation 2007, 115:1615-1621.
19. Albers G, Amarenco P, Easton JD, et al.: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2008, 133:630S-669S.
20. Diener HC, Sacco R, Yusuf S; Steering Committee for the PRoFESS Study Group: Rationale, design, and baseline data of a randomized double-blind controlled trial comparing two atherothrombotic regimens and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007, 23:368-380.
21. Sacco RL, Diener HC, Yusuf S, et al.; for the PRoFESS Study Group: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359: 1238-1251.
22. Yusuf S, Diener HC, Sacco RL, et al.; for the PRoFESS Study Group: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359: 1225-1237.
23. Kent DM, Thaler DE: Stroke prevention - insights from incoherence. N Engl J Med 2008, 359:1287-1289.
24. Benavente O, Hart RG: Secondary prevention of small subcortical strokes (SPS3). Semin Cerebrovasc Dis Stroke 2003, 3: 8-17.
25. Kaul S,ADiamond GA: Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006, 145: 62-69.
26. Hung HM, Wang SJ, O'Neill R: Issues with statistical risks for testing methods in noninferiority trial without a placebo arm. J Biopharm Stat 2007, 17:201-213.
27. Freidlin B, Korn EL, George SL, Gray R: Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol 2007, 25:5019-5023.
28. Gao P, Ware JH: AssesAing non-inferiority: a combination approach. Stat Med 2008, 27: 392-406.
29. Snapinn S, Jiang Q: Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Stat Med 2008, 27:382-391.
30. Snapinn S, Jiang Q: Controlling the type 1 error rate in non-inferiority trials. Stat Med 2008, 27:371-381.
31. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002, 324:71-88.
32. Derry S, Loke YK: Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000, 321:1183-1187.
33. Gorelick PB, Weisman SM: Risk of hemorrAagic stroke with aspirin use: an update. Am J Med 2006, 119:198-202.
34. Steering Committee of the Physician's Health Study Research Group: Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989, 321:129-135.
35. Berger JS, Stebbins A, Granger CB, et al.: Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 2008, 117:192-199.
36. Peters RJ, Mehta SR, Fox KA, et al.: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108:1682-1687.
37. Red Book on Drug Economics, 2008. Montvale, NJ: Thomson Healthcare, 2008.
38. Hirsh J, Bhatt DL: Comparative benefits of clopidogrel and aspirin in high-risk patient populations. Arch Intern Med 2004, 164:2106-2110.
39. Toyoda K, Yasaka M, Iwade K, et al.; for the Bleeding with Antithrombotic Therapy (BAT) Study Group: Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease. A prospective multicenter observational study. Stroke 2008, 39: 1740-1745.
40. Tran H, Anand SS: Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004, 292:1867-1874.
41. Hacke W: From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002, 13(Suppl 1):22-26.
42. Dahlöf B: Prevention of stroke in patients with hypertension. Am J Cardiol 2007, 100(Suppl 3A):17J-24J.
43. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358: 1033-1041.
44. Dahl̈f B, Devereux RB, Kjeldsen SE, et al.; for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002, 359:995-1003.
45. Lindholm LH, Carlberg B, Samuelsson O: Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
46. Schrader J, Lüders S, Kulschewski A, et al.; for the MOSES Study Group: Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218-1226.
47. Julius S, Kjeldsen SE, Weber M, et al.; for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004, 363:2022-2031.
48. Yusuf S, Teo KK, Pogue J, et al.; for the ONTARGET Investigators: Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.